Infinium Pharmachem share price
NSE: INFINIUMPharmaceuticals & Biotechnology
Infinium Pharmachem Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 2023 · Issue price ₹135
Last close ₹278.00up ₹2.95 (1.07%)
Share price at the NSE close on 29 Oct 2026. Previous close ₹275.05.
29 Oct: open ₹280.75, high ₹281.00, low ₹269.00
52-week range of traded prices to 29 Oct 2026
₹189.40Low, 30 Mar 2026₹324.50High, 6 Oct 2026
- Next results date: the board meets on 6 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. Market capitalisation: how it is worked out
- ₹433 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 35.65
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.58
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 10.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.17
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 9,50089.5% delivered
Results
Consolidated; ₹ crore.Infinium Pharmachem half-yearly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +21.8%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +41.8%
Half year to Mar 2026, against the half year before
- RevenueRevenue. The pill is the change in revenue against the half year before: this period's figure divided by that one's, less one, in per cent.
- ₹106 Crup 25.62%
- Net profitNet profit. The pill is the change in net profit against the half year before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹6.55 Crup 16.94%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 6.2%
Revenue by half year
Peak revenue ₹106 Cr, half year to Mar 2026; lowest ₹61 Cr, half year to Sep 2023
Net profit by half year, a loss in red
| ₹ crore | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | 61 | 74 | 83 | 73 | 84 | 106 |
| Net profit | 6 | 5 | 5 | 4 | 6 | 7 |
| Net margin | 10.2% | 6.9% | 5.8% | 5.1% | 6.7% | 6.2% |
Consolidated. The 7 half years from Mar 2023, the first on record. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share. No results on record for the half year to Mar 2023.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹190 Crup 21.79%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹12 Crup 49.17%
- Net margin
- 6.4%
Revenue by year
Peak revenue ₹190 Cr, year to Mar 2026; lowest ₹114 Cr, year to Mar 2023
Net profit by year, a loss in red
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 114 | 136 | 156 | 190 |
| Net profit | 9 | 11 | 8 | 12 |
| Net margin | 8.3% | 8.3% | 5.2% | 6.4% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Single segment, which carries all its revenue.
Valuation
Today, against the company's own history. Dividend yield is not shown: no dividend in the years on record.Infinium Pharmachem PE ratio and valuation
Price to earnings
At or below today's level on 54% of 238 trading days over the last year.
LowestHighest
Its median35.27Industry median28.22
Price to book
At or below today's level on 87% of 238 trading days over the last year.
LowestHighest
Its median2.94Industry median2.97
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −20.3% | +49.2% | −46.6% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1 year is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Infinium Pharmachem competitors and peers
Pharmaceuticals, 215 listed companies, priced on 29 Oct 2026. The table lists the 8 companies closest to Infinium Pharmachem in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Trident LifelineTLL | 516 | 22.77 | 4.53 | – | – | 24.0% | – | 0.00% |
 KRM AyurvedaKRMAYURVED | 502 | – | 4.37 | – | – | – | – | 0.00% |
 TranschemTRANSCHEM | 499 | 74.21 | 5.97 | −100.0% | +47.5% | 8.3% | −4.9% | 0.00% |
 Albert DavidALBERTDAVD | 438 | 19.42 | 1.12 | +11.4% | +258.5% | 5.8% | 4.1% | 0.65% |
 Haleos LabsHALEOSLABS | 432 | 27.34 | 2.02 | −3.1% | −8.5% | 7.7% | 7.4% | 0.11% |
 Jenburkt PharmaceuticalsJENBURPH | 385 | 11.73 | 1.95 | +9.1% | +1.2% | 17.8% | 19.2% | 2.37% |
 Medicamen BiotechMEDICAMEQ | 375 | – | 1.36 | +24.7% | – | – | 3.7% | 0.37% |
 Aarey Drugs & PharmaceuticalsAAREYDRUGS | 353 | – | – | −7.7% | – | – | 1.8% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Infinium Pharmachem announcements
Oct 2026
Sep 2026
22 Sep · Rating
Infinium Pharmachem share price by year
Each calendar year to 2025.Infinium Pharmachem share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 222.90 | −25.7% | 325.35 | 215.00 |
| 2024 | 299.90 | +27.6% | 386.80 | 183.05 |
| 2023 | 235.00 | – | 314.45 | 73.90 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2023 is from its first session, 17 Apr 2023.
Recent sessions
The 9 trading days to 28 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 28 Oct 2026 | 291.50 | 291.50 | 275.05 | 275.05 | 283.27 | 1,000 | 100.0% |
| 27 Oct 2026 | 296.50 | 296.50 | 286.00 | 286.00 | 291.25 | 1,000 | 100.0% |
| 26 Oct 2026 | 299.00 | 299.00 | 276.00 | 284.55 | 287.69 | 3,000 | 83.3% |
| 23 Oct 2026 | 303.50 | 303.50 | 284.00 | 286.00 | 291.81 | 4,000 | 100.0% |
| 22 Oct 2026 | 303.75 | 303.75 | 282.85 | 296.50 | 286.69 | 4,500 | 100.0% |
| 21 Oct 2026 | 303.50 | 303.50 | 281.00 | 297.70 | 290.80 | 2,000 | 100.0% |
| 19 Oct 2026 | 307.80 | 307.80 | 292.25 | 294.90 | 299.07 | 4,000 | 62.5% |
| 16 Oct 2026 | 319.50 | 319.50 | 302.00 | 305.05 | 304.40 | 5,000 | 100.0% |
| 15 Oct 2026 | 300.00 | 317.00 | 300.00 | 313.60 | 314.29 | 25,500 | 92.2% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus share history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 13 Sep 2023 | Bonus | 0.5000 | Holders received 1 bonus share for every 1 held. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout.
Company details
- NSE symbol
- INFINIUM
- ISIN
- INE0MRE01011
- Industry
- Pharmaceuticals & Biotechnology